Sort   by:  
 Page size 
ProteomicsEffect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053548 | Pride
Secondary aml Sndx-50469 Tasquinimod Cdk7 inhibitor Fhd-286 
UnknownEffective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Not available
S-EPMC8752621 | biostudies-literature
GenomicsEffective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
Treatment with Menin inhibitor (MI) disrupts interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressing mutant (mt)-NPM1. Following MI treatment, although clinical r...
ORGANISM(S): Homo sapiens 
2022-03-12 | GSE190719 | GEO
UnknownPatient-Specific Circulating Tumor DNA for Monitoring Response to Menin Inhibitor Treatment in Preclinical Models of Infant Leukemia.
Not available
S-EPMC11640178 | biostudies-literature
ProteomicsComparison of protein expression alterations in Menin inhibitor-sensitive and tolerant/resistant AML cells with or without Menin inhibitor treatment
AML MV4-11, OCI-AML3 and Menin inhibitor tolerant resistant MV4-11-MITR, and OCI-AML3-MITR cells were treated with 500 nM of SNDX-50469 for 48 hours to determine the global protein expression alterations that correlate with the tolerant/resistant phenotype compared to parental controls as well as th...
ORGANISM(S): Homo sapiens (Human) 
2026-09-03 | PXD053575 | Pride
Epigenetics Drug resistance Menin inhibitor Aml 
GenomicsOvercoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor [ChIP-seq]
Menin inhibitors (MI) disrupt the binding of Menin to MLL1 leading to repression of MLL1 or MLL1-fusion protein (FP) target genes, including reduced levels of HOXA9 and MEIS1 in AML with mtNPM1 or MLL1-r. While MIs are relatively well-tolerated and induce clinical remissions, these are often short-l...
ORGANISM(S): Homo sapiens 
2026-03-03 | GSE315339 | GEO
TranscriptomicsOvercoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor [RNA-seq]
Menin inhibitors (MI) disrupt the binding of Menin to MLL1 leading to repression of MLL1 or MLL1-fusion protein (FP) target genes, including reduced levels of HOXA9 and MEIS1 in AML with mtNPM1 or MLL1-r. While MIs are relatively well-tolerated and induce clinical remissions, these are often short-l...
ORGANISM(S): Homo sapiens 
2026-03-03 | GSE315341 | GEO
Genomics
AML cells with acquired resistance to menin inhibition
PRJNA1230395 | ENA
GenomicsEffective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
PRJNA788266 | ENA
GenomicsOvercoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor [ChIP-seq]
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor [ChIP-seq]
PRJNA1395661 | ENA
Sort   by:  
 Page size